Leaflet SASTRAVI 150mg / 37.5mg / 200mg film-coated tablets
Indicated for: Parkinson's disease
Route of administration: oral
Substance: levodopa + carbidopa + entacapone (antiparkinsonian agents)
ATC: N04BA03 (Nervous system | Dopaminergic agents | Dopa and dopa derivatives)
This medicine may affect your ability to drive or use machines.
This medicine may cause dizziness or vertigo.
May lower blood pressure and increase the risk of falls.
This medicine may cause drowsiness or reduced alertness.
Levodopa + Carbidopa + Entacapone is a combination medication used in the treatment of Parkinson's disease, particularly in patients experiencing motor fluctuations ('on-off' phenomena) associated with levodopa therapy. This combination enhances treatment efficacy and prolongs the duration of levodopa's action.
- Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain.
- Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, reducing side effects such as nausea.
- Entacapone is a COMT (catechol-O-methyltransferase) inhibitor that slows the breakdown of levodopa, extending its effect in the brain.
This combination is effective in alleviating symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and motor fluctuations. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.
Side effects may include nausea, diarrhea, dizziness, drowsiness, urine discoloration (brown-orange), and, in rare cases, hallucinations or compulsive behaviors. Regular monitoring is essential to adjust the treatment based on the progression of the disease.
General data about SASTRAVI 150mg / 37.5mg / 200mg
- Substance: levodopa + carbidopa + entacapone
- Date of last drug list: 01-03-2022
- Commercial code: W61574003
- Concentration: 150mg / 37.5mg / 200mg
- Pharmaceutical form: film-coated tablets
- Quantity: 100
- Product type: generic
- Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.
Pharmaceutical forms available for levodopa + carbidopa + entacapone
Concentrations available for levodopa + carbidopa + entacapone
- 100mg/25mg/200mg
- 125mg/31.25mg/200mg
- 150mg/37.5mg/200mg
- 175mg/43.75mg/200mg
- 200mg/50mg/200mg
- 20mg/5mg/20mg/ml
- 50mg/12.5mg/200mg
- 75mg/18.5mg/200mg
- 75mg/18.75mg/200mg